rhEPO联合GMl对缺氧缺血性脑病患儿神经功能修复的影响

Effects of recombinant human erythropoietin combined with GM1 on neurological repair in children patients with hypoxic ischemic encephalopathy

目的探讨重组人促红细胞生成素(recombination human erythropoietin,rhEPO)联合单唾液酸四已糖神经节苷脂(monosialoganglioside,GMl)对缺氧缺血性脑病(Hypoxic Ischemic Encephalopathy,HIE)患儿神经功能修复的影响。方法采用随机数字表法将本院2017年1月至2017年6月间收治的50例中、重度HIE患儿,分为观察组(n=25)和对照组(n=25)。对照组采用rhEPO治疗,观察组采用rhEPO联合GMl治疗,4周后比较两组患者的临床疗效、不良反应及预后。结果观察组治疗总有效率为96.00%,显著高于对照组76.00%(P<0.05);治疗后两组患儿新生儿期行为神经(Neonatalbehavioralneurologicalassessm,NBNA)评分均较治疗前明显升高,且观察组显著高于对照组(P<0.001);治疗后两组患儿智力发育指数(mental development index,MDI)和精神运动发育指数(psychomotor development index,PDI)评分均较治疗前升高,且观察组高于对照组(P<0.05);治疗后两组精神运动发育商(Developmental quotient,DQ)评分均较治疗前升高,且观察组高于对照组(P<0.05)。两组均未见明显不良反应,观察组预后显著优于对照组(P<0.05)。结论rhEPO联合GMl治疗中、重度HIE,可显著改善患儿神经功能预后。

Objective To explore the repair effects of recombinant human erythropoietin (rhEPO) combined with monosialoganglioside (GMl) on neurological function in children patients with neonatal hypoxic ischemic encephalopathy (HIE). Methods A total of 50 children patients with moderate-to-severe HIE admitted to our hospital from January 2017 to June 2017 were divided into observation group (n=25) and control group (n=25) according to the random number table method. Control group was given RhEPO treatment, and observation group was given rhEPO combined with GMl. The clinical efficacy of the two groups was compared after 4 weeks, and the adverse reactions and prognosis were compared between the two groups. Results The total effective rate of treatment in observation group was significantly higher than that in control group (96.00% vs 76.00%, P<0.05 ). The neonatal behavioral neurological assessment (NBNA) scores in the two groups after treatment were significantly higher than those before treatment, and the scores in observation group was significantly higher than that in control group ( P <0.001). The scores of mental development index (MDI) and psychomotor development index (PDI) in the two groups after treatment were higher than those before treatment, and the scores in observation group were higher than those in control group ( P<0.05 ). After treatment, the psychomotor development quotient (DQ) scores in the two groups were higher than those before treatment, and the score in observation group was higher than that in control group ( P<0.05 ). There were no significant adverse reactions in the two groups, and the prognosis in observation group was significantly better than that in control group ( P<0.05 ). Conclusion rhEPO combined with GM1 can significantly improve the neurological function and prognosis of children patients in the treatment of moderate-to-severe HIE.